Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.67 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.67 |
| ▸ | CLK1 | P49759 | 1/20 | 0.67 |
| ▸ | CLK2 | P49760 | 1/20 | 0.67 |
| ▸ | CLK3 | P49761 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.61 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.61 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.61 |
| ▸ | CSNK2A3 | Q8NEV1 | 3/20 | 0.61 |
| ▸ | CDC25B | P30305 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | MRE11 | P49959 | 1/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497020 | 1.00 | DYRK1A (0.67) | DYRK1ADYRK1BCLK1CLK2CLK3 | |
| SCHEMBL2880439 | 1.00 | DYRK1A (0.67) | DYRK1ADYRK1BCLK1CLK2CLK3 | |
| SCHEMBL29369746 | 0.87 | GSK3B (0.83) | DYRK1ADYRK1BGSK3BCSNK2A2CSNK2B | |
| SCHEMBL1249096 | 0.87 | GSK3B (0.83) | DYRK1ADYRK1BGSK3BCSNK2A2CSNK2B | |
| SCHEMBL2882197 | 0.87 | GSK3B (0.83) | DYRK1ADYRK1BGSK3BCSNK2A2CSNK2B | |
| SCHEMBL1249098 | 0.87 | GSK3B (0.83) | DYRK1ADYRK1BGSK3BCSNK2A2CSNK2B | |
| SCHEMBL497530 | 0.83 | CSNK2A2 (0.67) | DYRK1ADYRK1BCLK1GSK3BCSNK2A2 | |
| SCHEMBL1520306 | 0.83 | CSNK2A2 (0.67) | DYRK1ADYRK1BCLK1GSK3BCSNK2A2 | |
| SCHEMBL497529 | 0.83 | CSNK2A2 (0.67) | DYRK1ADYRK1BCLK1GSK3BCSNK2A2 | |
| SCHEMBL8188589 | 0.80 | DYRK1A (1.00) | DYRK1ADYRK1BCLK1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106214-B2 | 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors | MERCK SERONO SA (CH) | 2012-01-31 | — | — | US | disclosed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-1648452-B1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | MERCK SERONO SA (CH) | 2009-07-22 | — | — | EP | disclosed |
| EP-1648452-B1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | MERCK SERONO SA (CH) | 2009-07-22 | — | — | EP | disclosed |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-01-25 | — | — | US | disclosed |
| US-20040092561-A1 | Azolidinone-vinyl fused -benzene derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | ZAP70, BRCA1, ZYX | DYRK1A 3161/4885DYRK1B 2749/4885CLK1 4202/4885 |
| US-20040092561-A1 | Azolidinone-vinyl fused -benzene derivatives | BRCA1, ZAP70, ZYX | DYRK1A 3475/4885DYRK1B 3208/4885CLK1 4099/4885 |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | PI4K2B, PI4KA, PTK2B | DYRK1A 2093/4885DYRK1B 1813/4885CLK1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.